YOU ARE INVITED TO A PRESENTATION ON:

NUPLAZID (pimavanserin) 34mg capsules

See Important Safety Information, including **Boxed WARNING** below.

NUPLAZID® (pimavanserin) 34 mg: The First and Only FDA-Approved Treatment for Parkinson's Disease Psychosis

Addressing Serotonin Dysfunction in Parkinson's Disease Psychosis

PRESENTED BY:

Michelle Brewer, MD, PharmD
Medical Director Cole Neuroscience Center
University of Tennessee Medical Center
Knoxville, TN

DATE & LOCATION

Thursday, February 21, 2019
6:30 PM Eastern
At
Ruth's Chris Steak House
950 Volunteer Landing Lane
Knoxville, Tennessee 37915

PROGRAM OBJECTIVES

Review important facts about Parkinson's disease psychosis

- Diagnostic criteria
- Impact
- General treatment strategies

Discuss NUPLAZID® (pimavanserin)

- Proposed mechanism of action
- Efficacy
- Safety
- Administration

RSVP INFORMATION

Please call Michael Alm
at 865-850-6308 or email malm@acadia-pharm.com Please refer to

Meeting ID number: ACA0005832

Important Safety Information for NUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

Important Safety Information for NUPLAZID (pimavanserin) (Cont'd)

Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients for reduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration

Recommended dose: 34 mg taken orally once daily, without titration.

Indication

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Please see attached full Prescribing Information, also available at www.NUPLAZIDhcp.com.

NUPLAZID is available as 34 mg capsules, 17 mg tablets and 10 mg tablets.

ACADIA Pharmaceuticals is pleased to sponsor this program to provide information consistent with industry guidelines. This program is not an accredited CME program and is not designed to meet any training and/or educational requirements. In accordance with the PhRMA Code on Interactions With Health Care Professionals, attendance at this educational program is limited to only Health Care Professionals (Physicians, Nurse Practitioners, Physician Assistants, RNs, Clinical Pharmacists, Social Workers). Accordingly, attendance by guests or spouse is not permitted.

To comply with certain federal, state, and local laws that prohibit or limit the provision of meals to health care professionals and/or state employees, ACADIA Pharmaceuticals does not offer a complimentary meal to individuals who are subject to such restrictions. Attendees to whom such restrictions apply should not avail themselves of the complimentary meal. Please note that ACADIA Pharmaceuticals is required to report the value of a provided meal pursuant to applicable federal and state laws.

This invitation is non-transferrable.

ACADIA® Pharmaceuticals